# US 2021/0277115 A1 · Targeted therapy for small cell lung cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277115 A1
- Document ID: US20210277115A1
- Status: Published application
- Kind: A1
- Application number: 17/327,363
- Filed: 2021-05-21
- Published: 2021-09-09
- Earliest claimed: 2014-01-08
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Kipp Andrew Weiskopf; Julien Sage; Irving L. Weissman
- Web page: https://patentgrep.com/patent/US20210277115A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 38/1709: {from mammals}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 47/68033: {the drug being a maytansine}
- A61K 47/6857: {the tumour determinant being from lung cancer cell}
- A61K 47/6869: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2842: {against integrin beta1-subunit-containing molecules, e.g. CD29, CD49}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/3023: {Lung}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods are provided for treatment of lung cancers, particularly small cell lung cancer with targeted therapy, which optionally includes an agent that selectively blocks CD47 binding to SIRPα.

## Claims

### Claim at position 1

1-7. (canceled)

### Claim 8

A method of treating an individual with lung cancer, the method comprising:
administering to a human subject in need thereof a combination of (i) an agent that selectively blocks CD47 binding to SIRPα and (ii) a targeted therapeutic agent that specifically binds to one or more cell-surface antigens on lung cancer cells, in a dose effective to increase depletion of the lung cancer cells.

### Claim 9 (depends on 8)

The method of claim 8, wherein the agent that selectively blocks CD47 binding to SIRPα is an antibody.

### Claim 10 (depends on 9)

The method of claim 9, wherein the antibody specifically binds to CD47.

### Claim 11 (depends on 9)

The method of claim 9, wherein the antibody specifically binds to SIRPα.

### Claim 12 (depends on 8)

The method of claim 8, wherein the agent that selectively blocks CD47 binding to SIRPα is a soluble SIRPα polypeptide.

### Claim 13 (depends on 8)

The method of claim 8, wherein the agent that selectively blocks CD47 binding to SIRPα is a soluble CD47 polypeptide.

### Claim 14 (depends on 8)

The method of claim 8, wherein the one or more cell-surface antigens on lung cancer cells are selected from CD24, CD166, CD326, CD298, CD29, CD63, CD9, CD164, CD99, CD46, CD59, CD57, CD165, and EpCAM.

### Claim 15 (depends on 8)

The method of claim 8, wherein the combination of agents is administered simultaneously.

### Claim 16 (depends on 8)

The method of claim 8, wherein the combination of agents is administered sequentially.

### Claim 17 (depends on 8)

The method of claim 8, wherein the combination of agents is administered in overlapping dosing regimens

### Claim 18 (depends on 8)

The method of claim 8, wherein the individual is a human.

### Claim 19 (depends on 18)

The method of claim 18, wherein the lung cancer is small cell lung cancer.

### Claim 20 (depends on 19)

The method of claim 19, wherein said marker is selected from CD99, CD44 and EpCam.

### Claim 21 (depends on 8)

The method of claim 8, wherein the combination of agents provides for a synergistic effect.

### Claim 22 (depends on 10)

The method of claim 10, wherein the anti-CD47 antibody comprises an IgG4 Fc region.

### Claim 23 (depends on 22)

The method of claim 22 wherein the antibody is 5F9-G4.

### Claim 24

A method for the treatment of a lung cancer in a patient, the method comprising:
administering to said patient an effective dose of a targeted therapeutic agent that specifically binds to a cell surface antigen selected from CD99, CD44, EpCam, CD24, CD166, CD56, CD326, CD298, CD29, CD63, CD9, CD164, CD46, CD59, CD57, and CD165.
